[{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"$425.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foghorn\u00ae Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target\r\n","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"","productType":"Undisclosed","productStatus":"Undisclosed","date":"July 2020","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0.42999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.42999999999999999,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Merck","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Goldman Sachs & Co. LLC","pharmaFlowCategory":"D","amount":"$120.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foghorn Therapeutics Announces Pricing of Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Public Offering","leadProduct":"FHD-286","moa":"Allosteric ATPase","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Foghorn Therapeutics","amount2":0.12,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.12,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Goldman Sachs & Co. LLC","highestDevelopmentStatusID":"4","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"D","amount":"$380.0 million","upfrontCash":"$300.0 million","newsHeadline":"Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn\u2019s Proprietary Gene Traffic Control\u00ae Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"","productType":"Small molecule","productStatus":"Undisclosed","date":"December 2021","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0.38,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Discovery Platform","highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.38,"dosageForm":"Dosage Strength\/Form","sponsorNew":"Foghorn Therapeutics \/ Loxo Oncology","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics to Present Preclinical Data For FHD-286 at the 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Provides Update on Phase 1 Study of FHD-286 in Relapsed and\/or Refractory AML and MDS","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-286","moa":"Allosteric ATPase","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-609","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics to Present New Preclinical Data for BRG1\/BRM Inhibitor FHD-286 in Combination with Anti-PD-1 Antibody at Society for Immunotherapy of Cancer 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML to Be Presented at the American Society of Hematology Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Provides an Update on FHD-609","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-609","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286 in Relapsed and\/or Refractory AML\/MDS Patients","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and\/or Refractory AML","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","year":"2024","type":"Not Applicable","leadProduct":"FHD-909","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Foghorn Therapeutics","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"4","companyTruncated":"Foghorn Th.."},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"BVF Partners","pharmaFlowCategory":"D","amount":"$110.0 million","upfrontCash":"Undisclosed","newsHeadline":"Foghorn Therapeutics Raises $110 Million Through Direct Offering to Advance Pipeline","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","year":"2024","type":"Public Offering","leadProduct":"FHD-286","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Foghorn Therapeutics","amount2":0.11,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.11,"dosageForm":"","sponsorNew":"Foghorn Therapeutics \/ BVF Partners","highestDevelopmentStatusID":"6","companyTruncated":"Foghorn Th.."}]
Find Clinical Drug Pipeline Developments & Deals by Foghorn Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Market Place
Reset All
